SCHEMBL6436359

SCHEMBL6436359

COC[C@@H](NC(=O)OCc1ccccc1)C(=O)OC(C)(C)C

nearest known ligand 0.60

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CTSK P43235 9/20 0.60
SYK P43405 1/20 0.60
CTSS P25774 7/20 0.56
CTSL P07711 5/20 0.56
CTSB P07858 3/20 0.56
PPARA Q07869 1/20 0.54
ALDH1A1 P00352 1/20 0.52
ALOX15 P16050 1/20 0.52
TACR1 P25103 2/20 0.51
KYNU Q16719 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31372427 0.90 PPARA (0.60) CTSKSYKCTSSCTSLCTSB
SCHEMBL9470479 0.90 PPARA (0.67) CTSKSYKCTSSCTSLCTSB
SCHEMBL8138595 0.90 PPARA (0.60) CTSKSYKCTSSCTSLCTSB
SCHEMBL15569246 0.90 PPARA (0.60) CTSKSYKCTSSCTSLCTSB
SCHEMBL8749776 0.88 PPARA (0.56) CTSKSYKCTSSCTSLCTSB
SCHEMBL15354873 0.88 PPARA (0.61) CTSKSYKCTSSCTSLCTSB
SCHEMBL4387860 0.88 CTSK (0.64) CTSKCTSSCTSLCTSBALDH1A1
SCHEMBL527104 0.88 CTSK (0.64) CTSKCTSSCTSLCTSBALDH1A1
SCHEMBL527103 0.88 CTSK (0.64) CTSKCTSSCTSLCTSBALDH1A1
SCHEMBL21340066 0.87 SYK (0.66) CTSKSYKCTSSCTSLCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
CN-1318059-A Isoquinolines as urokinase inhibitors PFIZER (US) 2001-10-17 CN disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CTSK 129/4885SYK 4237/4885CTSS 180/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 CTSK 129/4885SYK 4237/4885CTSS 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.